Clinical Trial Update: A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating apatinib combined with capecitabine as adjuvant therapy for biliary carcinoma is ongoing with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Capecitabine (capecitabine)

Snippet

Sponsor: First Affiliated Hospital of Guangxi Medical University | Conditions: Biliary Carcinoma | Phase 2 | Status: UNKNOWN